drugset
drugset / Trial / NCT04631575

An Investigational Study of SHR6390 in Participants With Mild to Moderate Liver Impairment and Healthy Participants

NCT04631575 ↗

Phase 1 Unknown 24 enrolled Jiangsu HengRui Medicine Co., Ltd.
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this study is to investigate SHR6390 in participants with different levels of liver function

Timeline

Start
2020-12
Primary completion
2021-03
Completion
2021-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Dalpiciclib Small molecule — Oral

Indications

No indication recorded.